Leveraging Immunotherapy in Women’s Cancers: Expert Perspectives on Current Evidence and Practical Guidance in Cervical and Endometrial Cancers

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the webinar held May 14, 2021

This activity is valid from August 1, 2021 to August 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Although cervical and endometrial cancers are associated with high rates of positive clinical outcomes when detected early enough, many cases are not detected until they have reached an advanced stage. The management of patients with advanced/metastatic disease remains an important clinical and economic challenge. Pursuit of treatment options that may help to improve clinical efficacy and limit treatment-associated adverse events is an active area of investigation, with several options showing promise in recent studies. An understanding of the mechanisms underlying the development of these diseases has helped to inform new approaches to clinical management, which may improve outcomes for your patients.

Upon completion of this activity, participants will be able to:

  • Assess the current role of biomarkers to guide the application of immunotherapy for endometrial and cervical cancers

  • Describe key recent safety and efficacy data regarding immunotherapies for patients with endometrial and cervical cancers

  • Appraise current and emerging treatment combinations involving immunotherapy for women’s cancers

  • Outline evidence-based approaches to mitigate adverse events associated with immunotherapy for patients with endometrial and cervical cancers

  • Assess the managed care considerations of newer immune checkpoint inhibitors by exploring where these agents fit in the evolving endometrial and cervical cancers paradigm


Faculty: Stéphanie Gaillard, MD, PhD
Director, Gynecologic Cancer Trials
Assistant Professor of Oncology
Assistant Professor of Gynecology & Obstetrics
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center


Dr. Gaillard has served on an advisory board for Sermonix, Rigel, AstraZeneca, Elevar, and GSK. She has received a research grant from Pfizer, PharmaMar, AstraZeneca, Iovance, GSK, and Genentech. This presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue